Ropes & Gray represented FibroGen, Inc. in the transaction. FibroGen, Inc. (NASDAQ: FGEN) announced the sale of its China subsidiary, Fibrogen China, to AstraZeneca for approximately...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Kailera Therapeutics, Inc. on the transaction. Kailera Therapeutics, Inc. (“Kailera”) announced raising $400 million in Series A financing. Kailera announced its launch...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented SK Biopharmaceuticals on the transaction. SK Biopharmaceuticals announced it has entered into an global licensing agreement with radiotherapy company Full-Life Technologies (“Full-Life”)...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Erasca, Inc. on the deal. Erasca, Inc. (Nasdaq: ERAS), a precision oncology company, announced it has entered into an exclusive license agreement...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Allorion Therapeutics on the transaction. Allorion Therapeutics (Allorion) announced it entered into a global licensing agreement with Avenzo Therapeutics Inc. (Avenzo) to develop and...
You must be a Standard 1 Year member to access this content.
